Caplight Directory>Companies>Paradox Immunotherapeutics-preview>Paradoximmuno


Paradox Immunotherapeutics

Paradox Immunotherapeutics

Private
TorontoHealthcare & Life Scienceshttps://paradoximmuno.com

Last Round

Early Funding

Feb 25, 2025

Total Funding Raised

$10M

Company Overview

Paradox Immunotherapeutics is a biotechnology company developing antibody therapies for the treatment of rare protein misfolding diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

monoclonal antibodiesprotein misfolding diseasesmAbsantibody therapyamyloidosis treatmentpreclinical biotechbiologics discoveryimmunotherapyantibody discoveryrare diseasesselective protein targetingAL amyloidosisneurodegenerative disease

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Paradox Immunotherapeutics Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Paradox Immunotherapeutics Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Early FundingFeb 25, 2025
View all Funding Rounds

Key People

Founding team and executive leadership

Natalie J. Galant

Chief Executive Officer, Co-Founder

Founding Team

Paradox Immunotherapeutics Investors

Notable investors and investment history

InvestorRounds
SymBiosis Capital ManagementEarly Funding
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 25, 2025

    $10M raised in early funding.

  • Feb 25, 2025

    Selected for the Springboard Enterprises Life Sciences Program.

View all signals

Paradox Immunotherapeutics Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Paradox Immunotherapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Paradox Immunotherapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersToronto
Employee Range11
Year Founded2019
Last FundingFeb 25, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.





Caplight Logo




Use CasesInvestorsEmployees

CompaniesAll Companies

LegalPrivacy PolicyTerms of UseBrokerCheckForm CRS


Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.